The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, multicenter, prospective study of sacituzumab govitecan in recurrent glioblastoma.
 
William Kelly
Research Funding - Gilead Sciences
 
Christine Cordova
No Relationships to Disclose
 
Brian D. Vaillant
No Relationships to Disclose
 
Henriette Balinda
No Relationships to Disclose
 
Joel Michalek
No Relationships to Disclose
 
Andrea Gilbert
No Relationships to Disclose
 
John Floyd
No Relationships to Disclose
 
Andrew J. Brenner
Leadership - NanoTX
Stock and Other Ownership Interests - NanoTX; Plus Therapeutics
Honoraria - Seagen; Vascular Biogenics
Consulting or Advisory Role - Alamab Therapeutics; NanoTX; Plus Therapeutics; Vascular Biogenics
Research Funding - Gilead Sciences (Inst); Immunomedics (Inst); Plus Therapeutics (Inst); Upsher-Smith (Inst)
Patents, Royalties, Other Intellectual Property - I have intellectual property interest in NanoTx Therapeutics
Travel, Accommodations, Expenses - Vascular Biogenics